Stock Chart
PHVS
Type: SELL wallstreet
Strike: $45
Premium: $7.75
Expiry: Mar 19, 2027
Target: $46
Score: -84
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About PHVS - Pharvaris N.V. Ordinary Shares
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention …
Key Statistics
More PHVS Analysis
This PHVS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track PHVS's price movements with trendlines, gamma walls, and key support/resistance levels.